Andrew Kennedy, MD, speaks on the various approaches used in clinical practice to treat patients who have colorectal cancer with liver metastases.
Brian Hemphill, MD, provides insight on some of the challenges currently being faced in gastrointestinal malignancies and how molecular profiles of tumors will dramatically change outcomes for these patients.
Bert O'Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.
A supplemental biologics license application for pembrolizumab (Keytruda) for previously treated patients with advanced microsatellite instability-high cancer remains under review by the FDA.
Arturo Loaiza-Bonilla, MD, discusses the potential role of BRAF and CTNNB1 mutations in the survival difference between colorectal cancer patients with left- and right-sided tumors.
Tanios Bekaii-Saab, MD, discusses optimal sequencing with regorafenib (Stivarga) and TAS-102 (Lonsurf) in relapsed patients with metastatic colorectal cancer and combination regimens on the rise in the setting.
Rahmi Oklu, MD, PhD, discusses various approaches physicians use to treat patients who have CRC with liver metastases.
Axel Grothey, MD, discusses frontline therapy and maintenance strategies for patients with metastatic colorectal cancer.
Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.
Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.